BETH CHACHOUA (ISSY-LES-MOULINEAUX) Chiffre d'affaires, résultat, bilans sur SOCIETE.COM - 491002697
![Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors - Annals of Oncology Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/8fc38758-d8e7-4796-879e-95a8dc906a6c/gr1.jpg)
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors - Annals of Oncology
![Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors | British Journal of Cancer Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsj.bjc.6601550/MediaObjects/41416_2004_Article_BF6601550_Fig1_HTML.jpg)
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors | British Journal of Cancer
![Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors - Annals of Oncology Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d5524b1f-7071-4ac5-910c-ffc6fab16d7f/gr1_lrg.jpg)
Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors - Annals of Oncology
![Plasma MIP-1β levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib - Lung Cancer Plasma MIP-1β levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib - Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2d1d2a54-c482-4653-9151-699da0a4ead5/gr1.gif)
Plasma MIP-1β levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib - Lung Cancer
![Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer - Journal of Thoracic Oncology Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2039956535/2053504034/gr1.jpg)